Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial
Douglas R. Adkins(Washington University in St. Louis), Makoto Tahara(National Cancer Center Hospital East), Jessica Ley(Washington University in St. Louis), Justin Hoffman(Pfizer (United States)), Bohuslav Melichar(Palacký University Olomouc), Vyacheslay Vanchenko(Ivano-Frankivsk National Medical University), José López-Picazo González(Clinica Universidad de Navarra), Nataliia Komashko(Ivano-Frankivsk National Medical University), Assuntina G. Sacco(University of California San Diego), Trisha M. Wise‐Draper(University of Cincinnati), Siniša Radulović(Inserm), Xin Huang(Lineage Cell Therapeutics (United States)), Qi Shen(Qingdao University), Peter Oppelt(Washington University in St. Louis), Chia-Jui Yen(National Cheng Kung University), Jean-François Martini(Pfizer (United States)), Jin-Ching Lin(Changhua Christian Hospital), Holger Thurm(Pfizer (United States))
Cited by 43
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k